<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management and prognosis of X-linked adrenoleukodystrophy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management and prognosis of X-linked adrenoleukodystrophy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management and prognosis of X-linked adrenoleukodystrophy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc Engelen, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H795565158"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>X-linked adrenoleukodystrophy (ALD) is a peroxisomal disorder of beta-oxidation that results in accumulation of very long-chain fatty acids (VLCFAs) in all tissues. Patients with ALD are asymptomatic at birth but may develop adrenal failure, leukodystrophy, and/or myeloneuropathy (spinal cord disease and peripheral neuropathy). Disease manifestations and disease severity are highly variable among patients.</p><p>The treatment and prognosis of ALD will be reviewed here. Other aspects of ALD are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p class="headingAnchor" id="H2888209268"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>Patients diagnosed with ALD should be monitored for disease manifestations (leukodystrophy, myeloneuropathy, adrenal insufficiency), as detailed in the sections that follow  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H780070287"><span class="h2">MRI surveillance for leukodystrophy</span><span class="headingEndMark"> — </span>All neurologically asymptomatic males with confirmed ALD should undergo surveillance neuroimaging with brain magnetic resonance imaging (MRI); over half of males will eventually develop a progressive leukodystrophy, the clinical effects of which may be mitigated by early treatment. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Leukodystrophy'</a>.)</p><p>Routine surveillance in females is not recommended as leukodystrophy is rare in females [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Females with ALD'</a>.)</p><p>Based on the age distribution of developing an active, inflammatory brain lesion, 2022 consensus guidelines recommend the following brain MRI surveillance [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age 2 years: Baseline MRI without contrast (earlier brain MRI can be difficult to interpret due to incomplete myelination)</p><p class="bulletIndent1"><span class="glyph">●</span>Age 2 to 12 years: MRI with contrast every six months</p><p class="bulletIndent1"><span class="glyph">●</span>Age 12+ years: MRI annually, with contrast if lesion detected</p><p></p><p>Patients with lesions detected at any time by MRI should be referred urgently to a specialist or center with expertise in ALD [<a href="#rid2">2</a>]. (See <a class="local">'Early leukodystrophy'</a> below.)</p><p class="headingAnchor" id="H589665122"><span class="h2">Surveillance for myeloneuropathy</span><span class="headingEndMark"> — </span>The history and neurologic examination are the primary methods used to detect myeloneuropathy and polyneuropathy (myeloneuropathy). This can be done in conjunction with clinic visits or other testing  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>). Attention to the symptoms and signs of myeloneuropathy (eg, leg weakness, spasticity, gait ataxia, and sphincter dysfunction) is particularly important for patients who are 18 years of age and older, as onset is generally during adulthood for males and females. Virtually all males and most affected females develop myeloneuropathy. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Myeloneuropathy'</a>.)</p><p class="headingAnchor" id="H915666173"><span class="h2">Surveillance for adrenal insufficiency</span><span class="headingEndMark"> — </span>Male patients should be evaluated for adrenal function by measurement of plasma adrenocorticotropic hormone (ACTH) level and the rise in plasma cortisol level following ACTH stimulation. In addition, patients should also be evaluated for mineralocorticoid deficiency with plasma renin and serum electrolytes [<a href="#rid1">1</a>].</p><p>If initial adrenal testing is normal, follow-up testing should be performed every three to six months in males from six months to 10 years of age, and then yearly thereafter  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Adrenocorticotropic hormone stimulation test'</a>.)</p><p>Monitoring males for adrenal insufficiency is recommended over the course of the lifetime. However, early-life monitoring is more challenging due to the unpredictable secretory patterns and poor reference ranges for ACTH and cortisol in the first two years of life [<a href="#rid3">3,4</a>].</p><p>Testing is or will become abnormal in 90 percent of boys with neurologic signs and in 80 percent of men with myeloneuropathy [<a href="#rid5">5,6</a>]. ACTH levels are often increased already during the first year of life [<a href="#rid7">7</a>].</p><p>Females usually have normal adrenal function, and surveillance is not necessary.</p><p class="headingAnchor" id="H4106123239"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3485641710"><span class="h2">Asymptomatic with normal MRI</span><span class="headingEndMark"> — </span>For asymptomatic boys with ALD who have normal MRI of the brain, management consists of close monitoring with brain MRI surveillance (see <a class="local">'MRI surveillance for leukodystrophy'</a> above) and adrenal testing (see <a class="local">'Surveillance for adrenal insufficiency'</a> above), as described in the previous sections  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>).</p><p>Most of these patients are detected through newborn screening or testing performed due to an affected family member.</p><p>Routine MRI surveillance allows for early detection of onset of cerebral involvement and may facilitate optimal early treatment with hematopoietic cell transplantation (HCT) [<a href="#rid2">2,8</a>]. HCT should <strong>not</strong> be undertaken in boys without MRI evidence of cerebral involvement, because approximately one-half of this group will remain free of cerebral disease [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H4062970506"><span class="h2">Leukodystrophy</span></p><p class="headingAnchor" id="H3354051353"><span class="h3">Early leukodystrophy</span><span class="headingEndMark"> — </span>Early leukodystrophy includes patients with evidence of central nervous system involvement on MRI who are either asymptomatic or have only mild symptoms (eg, behavior changes, cognitive deficits, vision, or hearing impairment).</p><p class="headingAnchor" id="H1400945222"><span class="h4">Approach to treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span>Allogeneic HCT is the preferred treatment for patients with early leukodystrophy who have a matched donor  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>). (See <a class="local">'Allogeneic HCT'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HCT using autologous hematopoietic stem cells transfected with Lenti-D (<a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a>) may be an option (where available) for patients who do not have a suitable donor. (See <a class="local">'Autologous HCT with ex vivo gene therapy'</a> below.)</p><p></p><p>However, there are no randomized controlled trials of HCT for ALD, and evidence obtained using historical control groups may be questionable given that patients are now being detected at an earlier stage via screening protocols. In addition, the long-term safety of gene therapy is unknown.</p><p>In all cases, the risks of engraftment problems and graft-versus-host disease (GVHD) associated with allogeneic HCT will need to be weighed against risks of myelodysplastic syndrome (MDS) associated with autologous HCT using ex vivo gene therapy. (See <a class="local">'Allogeneic HCT'</a> below and <a class="local">'Autologous HCT with ex vivo gene therapy'</a> below.)</p><p>Other interventions such as dietary modifications (including Lorenzo's oil), statin medications, and other agents have not demonstrated clinical efficacy in limited observational studies and clinical trials. (See <a class="local">'Ineffective and unproven therapies'</a> below.)</p><p class="headingAnchor" id="H3395839398"><span class="h4">Allogeneic HCT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – Allogeneic HCT has emerged as the treatment of choice for individuals with early stages of cerebral involvement in ALD who have an appropriate matched related donor [<a href="#rid9">9-11</a>]. Stem cells can be harvested from a variety of hematologic sources, including peripheral blood, bone marrow, and umbilical cord blood. (See  <a class="medical medical_review" href="/z/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a> and  <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">"Donor selection for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1">The most appropriate candidates for HCT are boys with evidence of cerebral involvement on MRI who are early in their disease course (ie, mild or no signs and symptoms) [<a href="#rid5">5</a>]. However, the optimal timing for HCT is uncertain. For example, HCT is generally offered to asymptomatic patients with any evidence of active disease on MRI, even if MRI findings are quite subtle. Nevertheless, it is not known whether some of these subtle findings might spontaneously arrest without treatment [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1">The role of HCT in patients with myeloneuropathy is discussed below. (See <a class="local">'Myeloneuropathy'</a> below.)</p><p></p><p class="bulletIndent1">HCT does not appear to affect the course of adrenal dysfunction in patients with ALD, so patients require ongoing monitoring for adrenal dysfunction, and treatment, if necessary [<a href="#rid14">14</a>]. (See <a class="local">'Adrenal insufficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of HCT in the leukodystrophy of ALD is supported by several observational studies [<a href="#rid15">15-18</a>]. A retrospective report published in 2007 compared outcomes in 30 nontransplanted patients with early-stage cerebral ALD who were matched by neurologic disability and MRI severity scores with 19 transplanted early-stage cerebral ALD patients [<a href="#rid17">17</a>]. Five-year survival was considerably higher in the transplanted patients compared with the nontransplanted group (95 versus 54 percent, respectively).</p><p></p><p class="bulletIndent1">Other uncontrolled reports have found that HCT performed in the early stages of leukodystrophy for patients with mild disease is associated with higher survival rates compared with HCT performed in later stages for patients with more severe disease [<a href="#rid16">16,18</a>]. In a study of 94 boys with cerebral ALD who underwent HCT between 1982 and 1999, the overall estimated five-year survival was 56 percent [<a href="#rid16">16</a>]. Five-year survival was 92 percent among the subgroup of patients (n = 25) in which transplant was performed in the early stage of the illness, defined as having no or only one neurologic deficit (not including cognitive or behavioral symptoms) and mild abnormalities on brain MRI with a score ≤9 on a 34-point MRI severity scale (Loes scoring method), where 0 is normal and 34 is severely abnormal [<a href="#rid19">19</a>]. Although some studies suggest that neurologic outcome is good in those transplanted with a Loes score ≤9 [<a href="#rid18">18,20</a>], other studies have found severe, persistent cognitive deficits in those transplanted with a Loes score of 4.5 to 9 [<a href="#rid21">21</a>]. Therefore, a Loes score of 4.5 or lower may be preferable for selecting patients for HCT. The leading causes of death were progression of cerebral ALD in 21 patients and GVHD in 5 patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In addition to GVHD, HCT is associated with numerous short- and long-term complications that can affect many organ systems. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">"Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1588574171"><span class="h4">Autologous HCT with ex vivo gene therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – Autologous HCT using genetically modified cells may be an option for patients with early cerebral ALD, particularly those who do not have a matched related donor for allogeneic HCT [<a href="#rid22">22-24</a>]. This treatment is offered at a few specialized centers in the United States. Like allogenic HCT, autologous HCT using gene therapy is not expected to benefit myeloneuropathy or adrenal insufficiency.</p><p></p><p class="bulletIndent1">Gene therapy with autologous hematopoietic stem cells transfected with Lenti-D (<a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a>, eli-cel, a lentiviral vector containing manufactured <em>ABCD1</em> complementary deoxyribonucleic acid [DNA]) was granted accelerated approval by the US Food and Drug Administration (FDA) in September 2022 for the treatment of boys ages 4 to 17 years with early active cerebral ALD [<a href="#rid25">25</a>]. While the FDA approval is not restricted to children who lack a human leukocyte antigen (HLA)-matched donor, the studies that led to the approval mostly enrolled patients without an HLA-matched donor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – As reviewed below, autologous HCT with <a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a> may have comparable efficacy for treatment of early cerebral ALD compared with conventional allogeneic HCT and may be safer, particularly when compared with HLA-mismatched allogeneic HCT. However, given the relatively short follow-up of these patients, these results should be regarded as preliminary.</p><p></p><p class="bulletIndent1">The efficacy of autologous HCT with <a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a> was reported in a single-arm open-label study involving 17 boys with early-stage cerebral ALD who did not have an HLA-matched donor [<a href="#rid23">23</a>]. At 24 months post-transplantation, 88 percent of patients were alive with no major functional disabilities. Two patients died: one from disease progression that began during pretransplantation conditioning, and one who was withdrawn from the study and died from complications of subsequent allogeneic HCT. In the 15 surviving patients, none had evidence of GVHD.</p><p></p><p class="bulletIndent1">The FDA approval was based on additional data from two uncontrolled prospective studies, the results of which are available only from the FDA label [<a href="#rid24">24</a>]; full details of these studies have not been published. They were both open-label single-arm studies involving a total of 67 children with early cerebral ALD (ie, mild abnormalities on MRI with or without clinical symptoms). At the time of FDA approval, there were only 11 patients who had complete follow-up data and had symptomatic disease. In a post hoc analysis limited to these 11 patients, disease progression appeared to be slower compared with a historical control group consisting of seven untreated patients [<a href="#rid24">24</a>]. At 24 months, 72 percent (95% CI 35-90 percent) of treated patients were alive without major functional disability compared with 43 percent (95% CI 10-73 percent) of patients in the historical untreated control group. Given the small number of patients included in the analysis, it is unclear whether this finding is statistically significant. In addition, the control group was older (median 9 versus 6 years) and had greater MRI involvement (median MRI severity score 5 versus 2.5) at baseline, which may explain, at least in part, any potential difference in disease progression.</p><p></p><p class="bulletIndent1">A separate analysis available only in the FDA label reported the outcomes in patients treated with autologous HCT with <a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a> (n = 61) compared with historical controls who were treated with HLA-matched allogeneic HCT (n = 34) or HLA-mismatched allogeneic HCT (n = 17) [<a href="#rid24">24</a>]. Based on Kaplan-Meier curves, survival during the first nine months following treatment appeared to be better in patients treated with HLA-matched allogeneic HCT or autologous HCT using elivaldogene autotemcel compared with HLA-mismatched allogeneic HCT. However, the exact numbers are not provided, and it is unclear whether this finding was statistically significant. No patient treated with elivaldogene autotemcel developed acute or chronic GVHD during the first 24 months after treatment. A long-term follow-up study is ongoing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects and complications</strong> – The FDA label for <a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a> carries a boxed warning about the risk of hematologic malignancy and life-threatening MDS [<a href="#rid24">24,26</a>]. Important uncertainties remain. Data on long-term stability of the transduced cells are not yet available. The risk for genotoxic effects with lentiviral vectors is not fully characterized, though it appears to be low.</p><p></p><p class="bulletIndent1">HCT itself is associated with numerous short- and long-term complications that can affect many organ systems. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/122403.html" rel="external">"Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3002221382"><span class="h3">Advanced leukodystrophy</span><span class="headingEndMark"> — </span>Management of patients with advanced cerebral involvement is primarily supportive. HCT should not be undertaken in patients with advanced disease, since the limited available evidence suggests that HCT does not improve clinical outcomes in these individuals. (See <a class="local">'Allogeneic HCT'</a> above.)</p><p>Management often requires a team of providers from different specialties, including neurology, genetics, physiatry, endocrinology, speech therapy, ophthalmology, and audiology. The prognosis for patients with advanced cerebral ALD is generally poor, and involvement of a palliative care team is usually appropriate. (See <a class="local">'Prognosis'</a> below and  <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">"Pediatric palliative care"</a>.)</p><p class="headingAnchor" id="H4017089047"><span class="h3">Symptomatic management of leukodystrophy</span><span class="headingEndMark"> — </span>Patients with symptomatic leukodystrophy experience problems like those in other neurodegenerative disorders, and management principles are similar. These issues are discussed in greater detail in separate UpToDate topic reviews. They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Learning disabilities (see  <a class="medical medical_review" href="/z/d/html/614.html" rel="external">"Specific learning disorders in children: Educational management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive behavior (see  <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">"Management of neuropsychiatric symptoms of dementia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vision problems (see  <a class="medical medical_review" href="/z/d/html/6261.html" rel="external">"Vision screening and assessment in infants and children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Feeding difficulties (dysphagia, vomiting, aspiration) (see  <a class="medical medical_review" href="/z/d/html/14537.html" rel="external">"Aspiration due to swallowing dysfunction in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor coordination and ataxia (see  <a class="medical medical_review" href="/z/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Chronic progressive ataxias'</a> and  <a class="medical medical_review" href="/z/d/html/6234.html" rel="external">"Overview of the hereditary ataxias"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures (see  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>)</p><p></p><p>In addition, most patients with advanced disease have adrenal insufficiency and require replacement therapy. (See <a class="local">'Adrenal insufficiency'</a> below.)</p><p class="headingAnchor" id="H3405547774"><span class="h2">Myeloneuropathy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care </strong>–<strong> </strong>Treatment of patients with myeloneuropathy is supportive  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>) and is similar to that of other types of myelopathy [<a href="#rid27">27</a>]. Interventions are aimed at preventing and treating complications of myeloneuropathy (eg, spasticity, bladder dysfunction, sexual dysfunction, pressure ulcers). (See  <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease"</a>.)</p><p></p><p class="bulletIndent1">Treatment of ALD-related polyneuropathy is similar to other causes of polyneuropathy and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1">Interventions such as dietary modifications (including Lorenzo's oil), statin medications, and other pharmacologic agents have not demonstrated clinical efficacy in patients with myeloneuropathy. (See <a class="local">'Ineffective and unproven therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for HCT in</strong> <strong>myeloneuropathy without leukodystrophy</strong> – Myeloneuropathy without cerebral involvement does not appear to benefit from HCT [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">Limited data suggest that HCT does not slow progression of myeloneuropathy in ALD [<a href="#rid28">28</a>] and may exacerbate myelopathy symptoms. In a series of 14 adult males with cerebral myeloneuropathy who underwent HCT, 86 percent experienced motor disability exacerbations during the first six months following HCT [<a href="#rid29">29</a>]. Most patients also experienced new or aggravated bladder dysfunction during the transplant period. In another report of five boys who underwent HCT in childhood for cerebral ALD, three developed symptoms of myeloneuropathy in adulthood [<a href="#rid28">28</a>]. Autologous HCT with ex vivo gene therapy is also unlikely to benefit myeloneuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncertain role for HCT in</strong> <strong>myeloneuropathy and leukodystrophy</strong> – Based on limited data, HCT may be an option for some adult patients with myeloneuropathy who develop leukodystrophy and are identified in an early stage. As is the case with childhood ALD, adult patients with advanced neurologic disease are generally not considered candidates for HCT.</p><p></p><p class="bulletIndent1">Support for the use of HCT in adults with leukodystrophy comes largely from indirect evidence demonstrating benefits of HCT in boys with early cerebral ALD. (See <a class="local">'Allogeneic HCT'</a> above.)</p><p></p><p class="bulletIndent1">Data on HCT in adults with leukodystrophy are limited. In a retrospective study of 14 adult males with leukodystrophy who were treated with HCT in four European centers, median age at detection of cerebral disease was 33 years; five patients had established severe motor disability prior to HCT [<a href="#rid29">29</a>]. At a median follow-up of 65 months, overall survival was 57 percent. Severe motor dysfunction prior to HCT and/or bilateral involvement of the internal capsule on brain MRI were associated with poor survival (20 percent). Death was directly transplant-related in three patients, due to primary disease progression in advanced ALD in one patient, and due to secondary disease progression in the setting of multiorgan failure or non-engraftment in two patients. All eight survivors demonstrated radiographic arrest of cerebral demyelination, and none developed severe neurocognitive decline; however, most (five of eight) had deterioration of motor function.</p><p></p><p class="bulletIndent1">Further studies are needed to clarify the role of HCT in adults with cerebral myeloneuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational agents</strong> – Leriglitazone was evaluated in a randomized controlled trial of 116 ambulatory adult males with myeloneuropathy but no evidence of progressive leukodystrophy on MRI [<a href="#rid30">30</a>]. There was no benefit of leriglitazone compared with placebo on the primary outcome measure (six-minute walk test at week 96), although there was an effect on some secondary outcome measures (reduced body sway). Of note, leukodystrophy occurred in none of the treatment group compared with 5 percent in the placebo group. The possible preventive effect on the occurrence of leukodystrophy will be studied in an upcoming trial.</p><p></p><p class="headingAnchor" id="H3536678597"><span class="h2">Adrenal insufficiency</span><span class="headingEndMark"> — </span>Glucocorticoid replacement therapy (and in approximately 15 percent of cases also mineralocorticoid replacement) is essential for patients with adrenal insufficiency. However, it has no effect on neurologic abnormalities in ALD.</p><p>Additional details on the treatment of adrenal insufficiency, including hormone replacement therapy, treatment during stress conditions, and management of adrenal crisis, are provided in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a> and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p>Individuals with ALD and adrenal insufficiency should also have ongoing monitoring for mineralocorticoid deficiency, which may appear years or decades later. (See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children", section on 'Mineralocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Mineralocorticoid replacement for selected individuals'</a>.)</p><p class="headingAnchor" id="H4077217159"><span class="h1">INEFFECTIVE AND UNPROVEN THERAPIES</span></p><p class="headingAnchor" id="H3575148868"><span class="h2">Dietary modifications and Lorenzo's oil</span><span class="headingEndMark"> — </span>Based on the limited available evidence, dietary interventions (including Lorenzo's oil) do not appear to be effective in preventing or slowing disease progression in ALD. Until new data become available, we suggest <strong>not</strong> routinely using these interventions. In the United States, expanded access to Lorenzo's oil ended in May of 2017, and Lorenzo's oil is no longer available.</p><p>Despite the lack of proven efficacy, some families and caregivers may be highly motivated to try Lorenzo's oil, and some providers in areas outside of the United States may offer Lorenzo's oil to presymptomatic boys with ALD. If Lorenzo's oil is used, platelet counts and liver function tests should be monitored regularly. In addition, as previously discussed, patients should be closely monitored for onset of cerebral involvement since hematopoietic cell transplantation (HCT) is the preferred treatment for early cerebral ALD. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Neuroimaging'</a> and <a class="local">'Allogeneic HCT'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lorenzo's oil</strong> – Lorenzo's oil is a mixture of glycerol trioleate and glycerol trierucate that reduces the synthesis of very long-chain fatty acids (VLCFAs) by competitive inhibition of the enzyme responsible for elongation of saturated fatty acids [<a href="#rid31">31</a>]. There was initial enthusiasm due to the ability of Lorenzo's oil to impact biochemistry. However, subsequent small clinical trials found that these biochemical improvements did not result in clinical improvement or slowing of disease progression in treated patients [<a href="#rid32">32-34</a>].</p><p></p><p class="bulletIndent1">In two studies, administration of Lorenzo's oil to individuals with myeloneuropathy normalized plasma concentration of VLCFAs but did not stop disease progression in those with neurologic abnormalities [<a href="#rid32">32,33</a>]. Lorenzo's oil has also not had an impact on pre-existing endocrine dysfunction of the adrenal cortex and testis [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">In a single-arm open-label study of 89 asymptomatic boys (mean age 4.8 years at study entry) with ALD treated with Lorenzo's oil and moderate fat restriction and followed for a mean of 6.9 years, 24 percent developed MRI abnormalities and 11 percent developed clinically apparent neurologic abnormalities consistent with childhood cerebral ALD [<a href="#rid34">34</a>]. The lack of concurrent controls limits the ability to draw conclusions regarding the efficacy of treatment, though this rate of development of neurologic involvement appeared less than in historical controls [<a href="#rid35">35</a>]. Another limitation of the study is the relatively large number of participants who were either lost to follow-up (13 percent) or censored because they underwent HCT (16 percent). In a separate report of this cohort, Lorenzo's oil did not appear to have an effect on measures of oxidative stress and peroxidation [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Adverse effects of Lorenzo's oil reported in these studies included thrombocytopenia, elevated liver enzymes, gastrointestinal complaints, and gingivitis [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1">A placebo-controlled trial of Lorenzo's oil in myeloneuropathy was stopped early due to adverse effects, and results of the trial are not available [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restricting intake of fatty foods</strong> – Restriction of dietary VLCFAs can be accomplished by reducing the intake of fatty foods. However, this approach will not decrease the VLCFA concentration, because endogenous synthesis continues [<a href="#rid38">38</a>].</p><p></p><p class="headingAnchor" id="H834107176"><span class="h2">Statins and other agents</span><span class="headingEndMark"> — </span>Pharmacologic agents that have been proposed as potential therapeutic agents for ALD include statins and sodium phenyl acetate. We suggest not using these agents for treatment of ALD.</p><p>In a small observational study, <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">lovastatin</a> reduced plasma VLCFA levels in 12 affected individuals [<a href="#rid39">39</a>]. However, in a subsequent prospective randomized trial in 14 patients, the decrease in plasma VLCFA levels was small and transient, suggesting it is probably a nonspecific result of a concurrent decrease in plasma low-density lipoprotein (LDL) cholesterol [<a href="#rid40">40</a>]. Lovastatin did not reduce VLCFA levels in peripheral blood lymphocytes. The investigators concluded that the available data do not support use of lovastatin as a therapy to lower VLCFA levels in patients with ALD and that additional clinical trials with clinical end points are unwarranted.</p><p>Animal and ex vivo studies have suggested a potential therapeutic role for phenyl acetate (and its prodrug phenylbutyrate) [<a href="#rid41">41-43</a>]. The mechanism involves upregulation of <em>ABCD2</em> (ALD-related gene), thereby generating more ALD-related protein. There are no available clinical data on these agents in patients with ALD.</p><p class="headingAnchor" id="H2572219967"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>ALD is a progressive disorder. The prognosis is highly variable and depends on specific presentation [<a href="#rid44">44</a>]:</p><p class="headingAnchor" id="H1974020327"><span class="h2">Leukodystrophy</span><span class="headingEndMark"> — </span>The rate of disease progression in childhood leukodystrophy (cerebral ALD) is variable and appears to be related to the degree of brain inflammation and contrast enhancement on brain MRI [<a href="#rid45">45</a>]. In a report of 43 male patients with ALD, enhancement on initial T1-weighted MRI was present in 21 patients; at a mean follow-up of 14 months, disease progression demonstrated by MRI and neurologic scores was found in 18 (86 percent) [<a href="#rid45">45</a>]. For 22 patients with no enhancement on initial MRI, follow-up evaluations at a mean of 22 months demonstrated disease progression in only 4 of the 22 patients (18 percent).</p><p>Without treatment, rapid progression is most common, with total disability in six months to two years [<a href="#rid46">46</a>]. Spontaneous arrest of leukodystrophy, characterized by absence of symptom progression and lack of lesion growth or enhancement on brain MRI, occurs in a minority [<a href="#rid12">12</a>]. Patients with arrested ALD may remain stable for years but can eventually convert again to progressive ALD, so continued vigilance and monitoring is necessary. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Leukodystrophy'</a>.)</p><p>For boys who undergo successful hematopoietic cell transplantation (HCT) at an early stage of disease, five-year survival is &gt;90 percent [<a href="#rid16">16</a>]. However, HCT is not curative, and myelopathy symptoms may develop in adulthood [<a href="#rid28">28</a>]. (See <a class="local">'Allogeneic HCT'</a> above.)</p><p class="headingAnchor" id="H1528453728"><span class="h2">Myeloneuropathy</span><span class="headingEndMark"> — </span>Progression of myeloneuropathy occurs slowly over years to decades. Most male patients lose the ability to ambulate unassisted by age 50 years [<a href="#rid44">44</a>]. Neurogenic bladder is also nearly universal by this age. There are no available disease-modifying therapies to slow or prevent progression of myeloneuropathy.</p><p>Up to 60 percent of patients with myeloneuropathy eventually develop cerebral involvement and have a more rapidly progressive illness [<a href="#rid47">47</a>]. Cerebral involvement is typically associated with serious cognitive and behavioral disturbances progressing to total disability and early death [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H3152078286"><span class="h2">Adrenal insufficiency only</span><span class="headingEndMark"> — </span>Virtually all patients who present with isolated adrenal insufficiency develop progressive myelopathy by middle age.</p><p class="headingAnchor" id="H3085329940"><span class="h2">Female patients</span><span class="headingEndMark"> — </span>Almost 90 percent of female patients develop myelopathy symptoms by age 60 [<a href="#rid49">49</a>]. Progression is slower than in men [<a href="#rid50">50</a>]. Adrenal insufficiency and cerebral involvement are very rare.</p><p class="headingAnchor" id="H3824215492"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance</strong> – Patients diagnosed with X-linked adrenoleukodystrophy (ALD) should be monitored for disease manifestations (leukodystrophy, myeloneuropathy, adrenal insufficiency), as detailed above  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>). (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment options for ALD are targeted to specific disease manifestations  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic with normal brain MRI </strong>– For asymptomatic boys with ALD who have normal MRI of the brain, management consists of close monitoring, brain MRI surveillance, and adrenal testing  (<a class="graphic graphic_figure graphicRef141589" href="/z/d/graphic/141589.html" rel="external">figure 1</a>). (See <a class="local">'Asymptomatic with normal MRI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukodystrophy</strong> – The treatment of leukodystrophy varies by disease course (see <a class="local">'Early leukodystrophy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most boys with leukodystrophy who are early in their disease course and who have an appropriate matched donor, we suggest allogeneic hematopoietic cell transplantation (HCT) rather than supportive care alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). HCT should <strong>not</strong> be undertaken in patients with advanced neurologic disease as it has not been shown to improve clinical outcomes in this setting. Similarly, HCT should <strong>not</strong> be undertaken in presymptomatic boys who lack MRI evidence of cerebral involvement. (See <a class="local">'Allogeneic HCT'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For boys with early cerebral ALD who lack a matched human leukocyte antigen (HLA) donor, autologous HCT with ex vivo gene therapy (<a class="drug drug_general" data-topicid="139641" href="/z/d/drug information/139641.html" rel="external">elivaldogene autotemcel</a>, eli-cel) is an alternative treatment option that is offered at a few specialized centers in the United States. (See <a class="local">'Autologous HCT with ex vivo gene therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adult patients with advanced neurologic disease are generally not considered candidates for HCT. (See <a class="local">'Advanced leukodystrophy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myeloneuropathy</strong> – Benefit of HCT for myeloneuropathy in patients with ALD has not been demonstrated. Treatment of these patients is supportive and is similar to other types of myelopathy. Interventions are aimed at preventing and treating complications of myeloneuropathy (eg, spasticity, bladder dysfunction, sexual dysfunction, pressure ulcers). (See <a class="local">'Myeloneuropathy'</a> above and  <a class="medical medical_review" href="/z/d/html/4839.html" rel="external">"Chronic complications of spinal cord injury and disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adrenal insufficiency</strong> – For patients with adrenal insufficiency, with or without other manifestations of ALD, lifelong glucocorticoid replacement therapy is required. (See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a> and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unproven therapies</strong> – For all patients with ALD, we suggest <strong>not</strong> routinely using dietary modifications (including Lorenzo's oil) or statin medications to lower very long-chain fatty acid (VLCFA) levels (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These interventions have not demonstrated clinical efficacy in limited observational studies and clinical trials. (See <a class="local">'Ineffective and unproven therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– ALD is a progressive disorder. The prognosis depends on the disease manifestations. With symptomatic leukodystrophy, associated with growth and/or enhancement of lesions on brain MRI, rapid progression is common without treatment, leading to total disability over months to years and death within 10 years. Successful HCT for patients with early leukodystrophy is associated with prolonged survival. With myeloneuropathy, slower progression is typical, although many patients also develop leukodystrophy with more rapid progression to severe disability and death. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology 2022; 99:940.</a></li><li><a class="nounderline abstract_t">Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis 2021; 44:728.</a></li><li><a class="nounderline abstract_t">Kachwala I, Regelmann MO. Monitoring for and Management of Endocrine Dysfunction in Adrenoleukodystrophy. Int J Neonatal Screen 2022; 8.</a></li><li><a class="nounderline abstract_t">Regelmann MO, Kamboj MK, Miller BS, et al. Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. J Clin Endocrinol Metab 2018; 103:4324.</a></li><li class="breakAll">Raymond GV, Moser AB, Fatemi, A. X-linked adrenoleukodystrophy. In GeneReviews. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1315/ (Accessed on May 30, 2023).</li><li><a class="nounderline abstract_t">Huffnagel IC, Laheji FK, Aziz-Bose R, et al. The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. J Clin Endocrinol Metab 2019; 104:118.</a></li><li><a class="nounderline abstract_t">Dubey P, Raymond GV, Moser AB, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005; 146:528.</a></li><li><a class="nounderline abstract_t">Mallack EJ, Van Haren KP, Torrey A, et al. Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment. Neurology 2022; 99:e512.</a></li><li><a class="nounderline abstract_t">Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant 2005; 9 Suppl 7:55.</a></li><li><a class="nounderline abstract_t">Aubourg P, Blanche S, Jambaqué I, et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322:1860.</a></li><li><a class="nounderline abstract_t">Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20:857.</a></li><li><a class="nounderline abstract_t">Mallack EJ, van de Stadt S, Caruso PA, et al. Clinical and radiographic course of arrested cerebral adrenoleukodystrophy. Neurology 2020; 94:e2499.</a></li><li><a class="nounderline abstract_t">Carlson AM, Huffnagel IC, Verrips A, et al. Five men with arresting and relapsing cerebral adrenoleukodystrophy. J Neurol 2021; 268:936.</a></li><li><a class="nounderline abstract_t">Petryk A, Polgreen LE, Chahla S, et al. No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy. Bone Marrow Transplant 2012; 47:1377.</a></li><li><a class="nounderline abstract_t">Shapiro E, Krivit W, Lockman L, et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356:713.</a></li><li><a class="nounderline abstract_t">Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104:881.</a></li><li><a class="nounderline abstract_t">Mahmood A, Raymond GV, Dubey P, et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol 2007; 6:687.</a></li><li><a class="nounderline abstract_t">Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011; 118:1971.</a></li><li><a class="nounderline abstract_t">Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994; 15:1761.</a></li><li><a class="nounderline abstract_t">Raymond GV, Aubourg P, Paker A, et al. Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:538.</a></li><li><a class="nounderline abstract_t">Pierpont EI, Eisengart JB, Shanley R, et al. Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy. JAMA Neurol 2017; 74:710.</a></li><li><a class="nounderline abstract_t">Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818.</a></li><li><a class="nounderline abstract_t">Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med 2017; 377:1630.</a></li><li class="breakAll">Skysona (elivaldogene autotemcel) prescribing information. Available at: https://www.fda.gov/media/161640/download (Accessed on September 22, 2022).</li><li class="breakAll">FDA Roundup: September 20, 2022. Available at: https://www.fda.gov/news-events/press-announcements/fda-roundup-september-20-2022 (Accessed on September 22, 2022).</li><li class="breakAll">FDA halts Bluebird bio clinical trial after patient develops MDS. Available at: https://www.aabb.org/news-resources/news/article/2021/08/13/fda-halts-bluebird-bio-clinical-trial-after-patient-develops-mds (Accessed on February 03, 2022).</li><li><a class="nounderline abstract_t">Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep 2014; 14:486.</a></li><li><a class="nounderline abstract_t">van Geel BM, Poll-The BT, Verrips A, et al. Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study. J Inherit Metab Dis 2015; 38:359.</a></li><li><a class="nounderline abstract_t">Kühl JS, Suarez F, Gillett GT, et al. Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. Brain 2017; 140:953.</a></li><li><a class="nounderline abstract_t">Köhler W, Engelen M, Eichler F, et al. Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial. Lancet Neurol 2023; 22:127.</a></li><li><a class="nounderline abstract_t">Moser HW, Moser AB, Hollandsworth K, et al. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy. J Mol Neurosci 2007; 33:105.</a></li><li><a class="nounderline abstract_t">Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 1993; 329:745.</a></li><li><a class="nounderline abstract_t">van Geel BM, Assies J, Haverkort EB, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J Neurol Neurosurg Psychiatry 1999; 67:290.</a></li><li><a class="nounderline abstract_t">Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 2005; 62:1073.</a></li><li><a class="nounderline abstract_t">Bezman L, Moser HW. Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 1998; 76:415.</a></li><li><a class="nounderline abstract_t">Deon M, Wajner M, Sirtori LR, et al. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. J Neurol Sci 2006; 247:157.</a></li><li class="breakAll">A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00545597 (Accessed on August 09, 2017).</li><li><a class="nounderline abstract_t">Percy AK, Rutledge SL. Adrenoleukodystrophy and related disorders. Ment Retard Dev Disabil Res Rev 2001; 7:179.</a></li><li><a class="nounderline abstract_t">Pai GS, Khan M, Barbosa E, et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 2000; 69:312.</a></li><li><a class="nounderline abstract_t">Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 2010; 362:276.</a></li><li><a class="nounderline abstract_t">Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett 1998; 426:342.</a></li><li><a class="nounderline abstract_t">Gondcaille C, Depreter M, Fourcade S, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 2005; 169:93.</a></li><li><a class="nounderline abstract_t">Kemp S, Wanders RJ. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab 2007; 90:268.</a></li><li><a class="nounderline abstract_t">Kemp S, Huffnagel IC, Linthorst GE, et al. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol 2016; 12:606.</a></li><li><a class="nounderline abstract_t">Melhem ER, Loes DJ, Georgiades CS, et al. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. AJNR Am J Neuroradiol 2000; 21:839.</a></li><li><a class="nounderline abstract_t">Moser HW, Bergin A, Naidu S, Ladenson PW. Adrenoleukodystrophy. Endocrinol Metab Clin North Am 1991; 20:297.</a></li><li><a class="nounderline abstract_t">de Beer M, Engelen M, van Geel BM. Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy. Neurology 2014; 83:2227.</a></li><li><a class="nounderline abstract_t">van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001; 49:186.</a></li><li><a class="nounderline abstract_t">Engelen M, Barbier M, Dijkstra IM, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain 2014; 137:693.</a></li><li><a class="nounderline abstract_t">Huffnagel IC, Dijkgraaf MGW, Janssens GE, et al. Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J Rare Dis 2019; 14:30.</a></li></ol></div><div id="topicVersionRevision">Topic 141588 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36175155" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33373467" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35323197" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Monitoring for and Management of Endocrine Dysfunction in Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289543" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289543" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30252065" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812458" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35609989" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305618" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348839" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20626747" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32482842" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical and radiographic course of arrested cerebral adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32995952" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Five men with arresting and relapsing cerebral adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388279" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11085690" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073029" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21586746" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7847225" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adrenoleukodystrophy: a scoring method for brain MR observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292747" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418523" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neurocognitive Trajectory of Boys Who Received a Hematopoietic Stem Cell Transplant at an Early Stage of Childhood Cerebral Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892975" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976817" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976817" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976817" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976817" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115486" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : X-linked adrenoleukodystrophy: pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488625" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375456" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36681445" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901554" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350883" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449548" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009761" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9556301" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750542" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750542" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553934" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adrenoleukodystrophy and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10870849" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089986" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lovastatin in X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600263" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809314" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17092750" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27312864" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815658" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1879401" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25378668" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Frequent occurrence of cerebral demyelination in adrenomyeloneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220738" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480483" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30732635" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Disease progression in women with X-linked adrenoleukodystrophy is slow.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
